AJP - Gastrointestinal and Liver Physiology, Vol 268, Issue 5 849-G856, Copyright © 1995 by American Physiological Society

ARTICLES

Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties

M. Nishikawa, C. Miyazaki, F. Yamashita, Y. Takakura and M. Hashida
Department of Drug Delivery Research, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.

The recognition of 111In-labeled galactosylated superoxide dismutase (Gal-SOD) and galactosylated bovine serum albumin (Gal-BSA) by the liver was investigated in mice after intravenous injection. 111In-labeled galactosylated proteins were recovered in the liver by amounts that were highly dependent on the degree of galactose modification and the administered dose. The distribution patterns were analyzed based on a physiological pharmacokinetic model including an uptake process with Michaelis-Menten kinetics in the liver and hepatic plasma flow. The Michaelis constant of hepatic uptake of 111In-Gal-SOD was observed to inversely correlate with the number of galactose residues, without a significant change in maximum rate of uptake or extrahepatic clearance. This relation could be applied to 111In-Gal-BSA and other galactosylated proteins by using the surface density of galactose residues as a degree of modification, suggesting galactose density controls ligand recognition by the asialoglycoprotein receptor. The analysis also indicated that increasing galactose density higher than 1.0 x 10(-3) molecules/A2 did not affect the distribution of galactosylated proteins due to limitation by the hepatic plasma flow rate. In conclusion, efficient delivery of proteins modified with galactose to the liver will be achieved by controlling both the galactose density on the protein surface and the administered dose.

This article has been cited by other articles:

				Y. Ohno, H. Ishida, A. Hayashi, S. Kamagata, S. Hirobe, and K. Ishii The Mean Transit Time and Functional Image in Asialoglycoprotein Receptor Scintigraphy: A Novel Modality for Evaluating the Regional Dynamic Function of Hepatocytes J. Nucl. Med., December 1, 2002; 43(12): 1611 - 1615. [Abstract] [Full Text] [PDF]

				Y. Yamasaki, K. Sumimoto, M. Nishikawa, F. Yamashita, K. Yamaoka, M. Hashida, and Y. Takakura Pharmacokinetic Analysis of in Vivo Disposition of Succinylated Proteins Targeted to Liver Nonparenchymal Cells via Scavenger Receptors: Importance of Molecular Size and Negative Charge Density for in Vivo Recognition by Receptors J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 467 - 477. [Abstract] [Full Text] [PDF]

				K. Shirota, Y. Kato, K. Suzuki, and Y. Sugiyama Characterization of Novel Kidney-Specific Delivery System Using an Alkylglucoside Vector J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 459 - 467. [Abstract] [Full Text] [PDF]

				P. Opanasopit, K. Shirashi, M. Nishikawa, F. Yamashita, Y. Takakura, and M. Hashida In vivo recognition of mannosylated proteins by hepatic mannose receptors and mannan-binding protein Am J Physiol Gastrointest Liver Physiol, May 1, 2001; 280(5): G879 - G889. [Abstract] [Full Text] [PDF]

				K. Akamatsu, Y. Yamasaki, M. Nishikawa, Y. Takakura, and M. Hashida Development of a Hepatocyte-Specific Prostaglandin E1 Polymeric Prodrug and Its Potential for Preventing Carbon Tetrachloride-Induced Fulminant Hepatitis in Mice J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1242 - 1249. [Abstract] [Full Text]

				M. Nishikawa, S. Takemura, Y. Takakura, and M. Hashida Targeted Delivery of Plasmid DNA to Hepatocytes In Vivo: Optimization of the Pharmacokinetics of Plasmid DNA/Galactosylated Poly(L-Lysine) Complexes by Controlling their Physicochemical Properties J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 408 - 415. [Abstract] [Full Text]